SINGAPORE, Sept. 10, 2023 /PRNewswire-PRWeb/ — The combination of benmelstobart, anlotinib, and chemotherapy demonstrated significant benefits compared to placebo and chemotherapy in terms of median progression-free survival and overall survival for patients with extensive-stage…
